Computational tools to detect signatures of mutational processes in DNA from tumours: A review and empirical comparison of performance.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 09 05 2019
accepted: 01 08 2019
entrez: 13 9 2019
pubmed: 13 9 2019
medline: 17 3 2020
Statut: epublish

Résumé

Mutational signatures refer to patterns in the occurrence of somatic mutations that might be uniquely ascribed to particular mutational process. Tumour mutation catalogues can reveal mutational signatures but are often consistent with the mutation spectra produced by a variety of mutagens. To date, after the analysis of tens of thousands of exomes and genomes from about 40 different cancer types, tens of mutational signatures characterized by a unique probability profile across the 96 trinucleotide-based mutation types have been identified, validated and catalogued. At the same time, several concurrent methods have been developed for either the quantification of the contribution of catalogued signatures in a given cancer sequence or the identification of new signatures from a sample of cancer sequences. A review of existing computational tools has been recently published to guide researchers and practitioners through their mutational signature analyses, but other tools have been introduced since its publication and, a systematic evaluation and comparison of the performance of such tools is still lacking. In order to fill this gap, we have carried out an empirical evaluation of the main packages available to date, using both real and simulated data. Among other results, our empirical study shows that the identification of signatures is more difficult for cancers characterized by multiple signatures each having a small contribution. This work suggests that detection methods based on probabilistic models, especially EMu and bayesNMF, have in general better performance than NMF-based methods.

Identifiants

pubmed: 31513583
doi: 10.1371/journal.pone.0221235
pii: PONE-D-19-13159
pmc: PMC6741849
doi:

Substances chimiques

DNA, Neoplasm 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0221235

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mol Biol Cell. 2017 Jan 1;28(1):192-200
pubmed: 28035050
Nat Commun. 2017 Nov 3;8(1):1315
pubmed: 29101368
Bioinformatics. 2018 Jan 15;34(2):330-337
pubmed: 29028923
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Eur J Epidemiol. 2019 May;34(5):439-445
pubmed: 30623292
Bioinformatics. 2015 Nov 15;31(22):3673-5
pubmed: 26163694
Genome Biol. 2016 Aug 24;17(1):178
pubmed: 27557938
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Nat Genet. 2016 Jun;48(6):600-606
pubmed: 27111033
IEEE Trans Pattern Anal Mach Intell. 2013 Jul;35(7):1592-605
pubmed: 23681989
Curr Opin Oncol. 2018 Jan;30(1):61-67
pubmed: 29076965
Exp Mol Med. 2018 Feb 9;50(2):e442
pubmed: 29422544
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Bioinformatics. 2017 Jan 1;33(1):8-16
pubmed: 27591080
Nucleic Acids Res. 2018 Jul 2;46(W1):W102-W108
pubmed: 29790943
BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):152
pubmed: 30999866
PLoS Comput Biol. 2021 Jun 28;17(6):e1009119
pubmed: 34181655
Oncotarget. 2017 Aug 24;8(54):91950-91957
pubmed: 29190888
PLoS Genet. 2015 Dec 02;11(12):e1005657
pubmed: 26630308
Nature. 1999 Oct 21;401(6755):788-91
pubmed: 10548103
BMC Bioinformatics. 2018 Jun 14;19(1):224
pubmed: 29898651
Brief Bioinform. 2019 Jan 18;20(1):77-88
pubmed: 28968631
BMC Genomics. 2018 Nov 28;19(1):845
pubmed: 30486787
Genome Biol. 2013 Apr 29;14(4):R39
pubmed: 23628380
Nucleic Acids Res. 2018 Jan 4;46(D1):D964-D970
pubmed: 29145625
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Nucleic Acids Res. 2017 Jul 3;45(W1):W514-W522
pubmed: 28472504
Cell. 2019 May 2;177(4):821-836.e16
pubmed: 30982602
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
BMC Bioinformatics. 2016 Apr 18;17:170
pubmed: 27091472
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Commun. 2015 Dec 07;6:8866
pubmed: 26638776
Nat Commun. 2018 May 1;9(1):1744
pubmed: 29717121

Auteurs

Hanane Omichessan (H)

CESP (UMR INSERM 1018), Université Paris-Saclay, UPSud, UVSQ, Villejuif, France.
Gustave Roussy, Villejuif, France.

Gianluca Severi (G)

CESP (UMR INSERM 1018), Université Paris-Saclay, UPSud, UVSQ, Villejuif, France.
Gustave Roussy, Villejuif, France.
Cancer Epidemiology Centre, Cancer Council Victoria, and Centre for Epidemiology and Biostatistics, Melbourne School for Population and Global Health, The University of Melbourne, Melbourne, Australia.

Vittorio Perduca (V)

CESP (UMR INSERM 1018), Université Paris-Saclay, UPSud, UVSQ, Villejuif, France.
Laboratoire de Mathématiques Appliquées à Paris 5-MAP5 (UMR CNRS 8145), Université Paris Descartes, Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH